Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)

Key Points

• Traders bought an unusually large volume of calls — 24,027 call options, about 99% above the average — coinciding with NVAX shares rising roughly 9.3% on heavy volume, signaling short‑term bullish options activity.
• Novavax signed a non‑exclusive Matrix‑M license with Pfizer that pays $30M upfront, up to $500M in milestones and mid‑single‑digit royalties, which could create recurring licensing/royalty revenue if Pfizer programs succeed.
• Outlook remains mixed: analysts and hedge funds are split (average rating: “Hold,” $11.25 target), while fundamentals show recent revenue declines and EPS misses and some firms (e.g., BofA) cite execution and cash‑flow risks.

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 24,027 call options on the company. This represents an increase of 99% compared to the average volume of 12,104 call options.

More Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax signed a non‑exclusive Matrix‑M license with Pfizer that pays $30M upfront, up to $500M in development/sales milestones and high mid‑single‑digit royalties — immediate cash plus sizeable upside if programs succeed. Press Release
• Positive Sentiment: Expanding Matrix‑M licensing deals are being viewed as a proof point for a recurring licensing/royalty business model that could boost long‑term revenue and valuation upside; some sell‑side analysts have reiterated buy ratings on this thesis. TipRanks: Buy Rating Coverage
• Neutral Sentiment: Market commentators and valuation pieces are re‑running models to price the new deal into NVAX forecasts; some coverage focuses on how materially the Pfizer license changes discounted cash‑flow assumptions. Yahoo Finance: Valuation Assessment
• Neutral Sentiment: Major news outlets (Reuters) confirmed the licensing agreement, which helps cement the development/partnering narrative but does not guarantee milestones will be achieved. Reuters: Deal Coverage
• Negative Sentiment: Bank of America reiterated a Sell rating, arguing execution risk, long‑dated cash flows and weak COVID market prospects still undermine profitability — the license reduces but does not eliminate these risks. TipRanks: BofA Sell Note
• Negative Sentiment: Underlying fundamentals remain mixed: recent quarterly results showed revenue declines year‑over‑year and prior EPS misses; Matrix‑M royalties/milestones are contingent on Pfizer program success, so material cash flow depends on future events. Zacks: Deal + Financial Context

Hedge Funds Weigh In On Novavax

A number of institutional investors have recently added to or reduced their stakes in NVAX. Flagship Harbor Advisors LLC purchased a new stake in Novavax during the fourth quarter valued at approximately $33,000. Shah Capital Management raised its position in shares of Novavax by 23.3% during the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company's stock worth $97,835,000 after purchasing an additional 2,747,000 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Novavax during the fourth quarter worth $126,000. SG Americas Securities LLC boosted its stake in Novavax by 6.3% during the fourth quarter. SG Americas Securities LLC now owns 976,388 shares of the biopharmaceutical company's stock worth $6,561,000 after buying an additional 57,705 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Novavax in the 3rd quarter valued at $138,000. Institutional investors own 53.04% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on NVAX shares. Cantor Fitzgerald assumed coverage on Novavax in a report on Friday, October 24th. They issued an "overweight" rating and a $18.00 target price on the stock. BTIG Research reaffirmed a "buy" rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday. HC Wainwright boosted their price target on Novavax from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Thursday, October 23rd. Wall Street Zen lowered shares of Novavax from a "hold" rating to a "sell" rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Novavax in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $11.25.

Novavax Stock Up 9.3%

Shares of NVAX stock traded up $0.76 on Wednesday, hitting $8.96. 7,413,191 shares of the stock were exchanged, compared to its average volume of 5,683,077. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $10.64. The firm has a market capitalization of $1.46 billion, a P/E ratio of 5.01 and a beta of 2.37. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The business has a 50-day moving average of $7.01 and a 200 day moving average of $7.67.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.08) by ($0.17). The firm had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. Novavax had a net margin of 32.10% and a negative return on equity of 217.02%. The business's revenue was down 16.7% compared to the same quarter last year. During the same period last year, the business earned ($0.76) earnings per share. Equities analysts anticipate that Novavax will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.